Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $210.5 million.

  • United Therapeutics' Capital Expenditures rose 17516.34% to $210.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.3 million, marking a year-over-year increase of 8209.64%. This contributed to the annual value of $246.5 million for FY2024, which is 698.78% up from last year.
  • United Therapeutics' Capital Expenditures amounted to $210.5 million in Q3 2025, which was up 17516.34% from $62.2 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Capital Expenditures ranged from a high of $210.5 million in Q3 2025 and a low of $10.6 million during Q1 2021
  • For the 5-year period, United Therapeutics' Capital Expenditures averaged around $57.1 million, with its median value being $45.1 million (2024).
  • As far as peak fluctuations go, United Therapeutics' Capital Expenditures skyrocketed by 47398.37% in 2021, and later tumbled by 4405.1% in 2022.
  • United Therapeutics' Capital Expenditures (Quarter) stood at $70.6 million in 2021, then plummeted by 44.05% to $39.5 million in 2022, then surged by 99.24% to $78.7 million in 2023, then increased by 10.17% to $86.7 million in 2024, then soared by 142.79% to $210.5 million in 2025.
  • Its Capital Expenditures was $210.5 million in Q3 2025, compared to $62.2 million in Q2 2025 and $74.9 million in Q1 2025.